PolyPid (NASDAQ:PYPD) Coverage Initiated at Craig Hallum

Research analysts at Craig Hallum started coverage on shares of PolyPid (NASDAQ:PYPD) in a research note issued to investors on Monday, Benzinga reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. Craig Hallum’s price target suggests a potential upside of 199.63% from the company’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of PolyPid in a report on Wednesday, October 2nd.

PolyPid Price Performance

PYPD stock opened at $3.34 on Monday. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.95 and a current ratio of 0.95. The business has a 50-day simple moving average of $3.48 and a two-hundred day simple moving average of $3.87. The company has a market capitalization of $16.02 million, a P/E ratio of -0.33 and a beta of 1.31. PolyPid has a 52-week low of $2.95 and a 52-week high of $9.20.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($1.25) EPS for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.26. Research analysts expect that PolyPid will post -4.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PolyPid stock. Rosalind Advisors Inc. grew its holdings in shares of PolyPid Ltd. (NASDAQ:PYPD) by 62.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 679,168 shares of the company’s stock after buying an additional 262,368 shares during the period. PolyPid accounts for approximately 1.5% of Rosalind Advisors Inc.’s holdings, making the stock its 18th biggest position. Rosalind Advisors Inc. owned 14.16% of PolyPid worth $2,336,000 at the end of the most recent quarter. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.